Literature DB >> 9144854

PET in oncology: will it replace the other modalities?

C K Hoh1, C Schiepers, M A Seltzer, S S Gambhir, D H Silverman, J Czernin, J Maddahi, M E Phelps.   

Abstract

Medical imaging technology is rapidly expanding and the role of each modality is being redefined constantly. PET has been around since the early sixties and gained clinical acceptance in oncology only after an extreme number of scientific publications. Although PET has the unique ability to image biochemical processes in vivo, this ability is not fully used as a clinical imaging tool. In this overview, the role of PET in relation to other tumor imaging modalities will be discussed and the reported results in the literature will be reviewed. In predicting the future of PET, technical improvements of other imaging modalities need to be dealt with. The fundamental physical principles for image formation with computed tomography (CT), ultrasound (US), magnetic resonance imaging (MRI), photon-emission tomography (PET), and single photon emission CT (SPECT) will not change. The potential variety of radiopharmaceuticals which may be developed is unlimited, however, and this provides nuclear imaging techniques with a significant advantage and adaptive features for future biologic imaging. The current applications of PET in oncology have been in characterizing tumor lesions, differentiating recurrent disease from treatment effects, staging tumors, evaluating the extent of disease, and monitoring therapy. The future developments in medicine may use the unique capabilities of PET not only in diagnostic imaging but also in molecular medicine and genetics. The articles discussed in this review were selected from a literature search covering the last 3 years, and in which comparisons of PET with conventional imaging were addressed specifically. PET studies with the glucose analogue fluorine-18-labeled deoxyglucose (FDG) have shown the ability of detecting tumor foci in a variety of histological neoplasms such as thyroid cancer, breast cancer, lymphoma, lung cancer, head and neck carcinoma, colorectal cancer, ovarian carcinoma, and musculoskeletal tumors. Also, the contribution of the whole body PET (WBPET) imaging technique in diagnosis will be discussed. In the current health care environment, a successful imaging technology must not only change medical management but also demonstrate that those changes improve patient outcome.

Entities:  

Mesh:

Year:  1997        PMID: 9144854     DOI: 10.1016/s0001-2998(97)80042-6

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  21 in total

1.  FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; M Tokunaga; Y Koyama; N Sato; K Endo
Journal:  Skeletal Radiol       Date:  2003-01-24       Impact factor: 2.199

2.  Is 11C-choline the most appropriate tracer for prostate cancer? For.

Authors:  Ferruccio Fazio; Maria Picchio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-02       Impact factor: 9.236

3.  FDG-PET: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

4.  Future of positron-emission tomography in oncology.

Authors:  J E Niederhuber
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

5.  Cost-effectiveness of positron emission tomography in breast cancer.

Authors:  J Scott Sloka; Peter D Hollett; Maria Mathews
Journal:  Mol Imaging Biol       Date:  2005 Sep-Oct       Impact factor: 3.488

6.  Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography.

Authors:  D H Park; K H Kim; S Y Park; B H Lee; C W Choi; S Y Chin
Journal:  Korean J Radiol       Date:  2000 Jan-Mar       Impact factor: 3.500

7.  The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Authors:  B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-22       Impact factor: 9.236

8.  Flare response versus disease progression in patients with non-small cell lung cancer.

Authors:  Khalsa Al-Nabhani; Rizwan Syed; Athar Haroon; Omar Almukhailed; Jamshed Bomanji
Journal:  J Radiol Case Rep       Date:  2012-11-01

9.  Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine.

Authors:  Alexander Becherer; Georgios Karanikas; Monica Szabó; Georg Zettinig; Susanne Asenbaum; Christine Marosi; Christine Henk; Patrick Wunderbaldinger; Thomas Czech; Wolfgang Wadsak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-23       Impact factor: 9.236

10.  Effect of rolipram on relative 14C-deoxyglucose uptake in inflammatory lesions and skeletal muscle.

Authors:  Miho Shukuri; Masahiro Terai; Rie Hosoi; Tsunehiko Nishimura; Antony Gee; Osamu Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.